Brelovitug Hits Primary Endpoint in Second Phase 3, Completing Registrational Package
MIRM sits 47% above its 52-week low of $63.232.
Summary
Brelovitug met the primary endpoint in AZURE-4, the second of two Phase 3 studies that form Mirum's U.S. registration package for chronic hepatitis delta virus. The study enrolled 113 treatment-naive patients, 53% of them cirrhotic. At Week 24, 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks achieved the combined virologic response and ALT normalization endpoint versus 0% in the delayed-treatment arm, with p≤0.0001 for both. Flu-like illness was the most common adverse event, at 17.2% with 300 mg weekly and 18.5% with 900 mg every four weeks, and there were no new safety signals. This follows the September AZURE-1 win and closes out the registrational data Mirum needs. The company plans a BLA submission in the first half of 2027 with a potential U.S. launch in Q4 2027. Long-term AASLD data showed deepening viral suppression and ALT normalization with extended treatment, including in patients with cirrhosis.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — AZURE-4 enrolled 113 treatment-naive patients (53% cirrhotic); flu-like illness was the most common adverse event at 17.2% (300 mg QW) and 18.5% (900 mg Q4W), with no new safety signals.
At the time of this announcement, MIRM was trading at $93.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.